Heparin Dosing for Thrombotic Microangiopathy (TMA)
Heparin is NOT recommended as a primary treatment for TMA and should generally be avoided in this condition. The evidence shows that heparin can be harmful in TMA, potentially worsening microvascular thrombosis, and there is no controlled data supporting its efficacy 1.
Why Heparin Should Be Avoided in TMA
The pathophysiology of TMA involves microvascular platelet aggregation and endothelial injury, not the typical coagulation cascade that heparin targets. Platelet transfusions and heparin have been associated with deleterious effects in TMA, as they can add to the severity and extent of microvascular thrombi formation 1.
Key Evidence Against Heparin Use:
- A comprehensive review of TMA treatment found that heparin use showed "variable results and no controlled study supports their use" 1
- The primary effective therapy for TMA (particularly TTP) is plasma exchange, which achieves >80% response rates 1
- Heparin may actually worsen outcomes by promoting platelet activation in the already prothrombotic microenvironment
Important Clinical Caveat: HIT-Associated TMA
There is ONE critical exception where anticoagulation becomes necessary: If a patient with TMA develops heparin-induced thrombocytopenia (HIT), you must immediately switch from heparin to a direct thrombin inhibitor.
Recognizing HIT in TMA Patients:
- TMA patients may be predisposed to HIT due to increased platelet activation and PF4 release 2, 3
- Suspect HIT if thrombocytopenia persists or recurs despite appropriate TMA therapy (plasma exchange)
- Check PF4/heparin antibodies if intermediate or high pretest probability
- If HIT is confirmed, switch to lepirudin or another direct thrombin inhibitor immediately 3
If Anticoagulation Is Absolutely Required
If you must anticoagulate a TMA patient for another indication (e.g., concurrent DVT, atrial fibrillation), use the FDA-approved therapeutic heparin dosing 4:
Weight-based IV regimen:
- Initial bolus: 80 units/kg IV
- Continuous infusion: 18 units/kg/hour
- Target aPTT: 1.5-2 times control (46-70 seconds)
- Monitor aPTT every 4 hours initially, then at appropriate intervals
Alternative fixed-dose regimen:
- Initial bolus: 5,000 units IV
- Continuous infusion: 20,000-40,000 units/24 hours (approximately 32,000 units/day)
Recommended Approach for TMA
Instead of heparin, focus on:
- Immediate plasma exchange - the only proven therapy for TTP with 80-90% survival 1
- Avoid platelet transfusions unless life-threatening bleeding occurs
- Identify and treat the underlying cause (infection, malignancy, autoimmune disease, transplant-related)
- Monitor closely for HIT if any heparin exposure has occurred
- Consider glucocorticoids as adjunctive therapy, though evidence is limited 1
Bottom line: Do not use heparin as treatment for TMA itself. Only use therapeutic anticoagulation if there is a separate, compelling indication, and remain vigilant for HIT development.